494 related articles for article (PubMed ID: 18472686)
1. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K
Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
[TBL] [Abstract][Full Text] [Related]
2. Updating practices in an evolving IV iron and anemia environment: practical solutions.
Amerling R; Easom A; Juergensen P
Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
[TBL] [Abstract][Full Text] [Related]
3. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
Easom A
Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
[TBL] [Abstract][Full Text] [Related]
4. Supporting epoetin alfa stimulated erythropoiesis: identifying appropriate iron levels: case study of the anemic patient.
Sasak C
Nephrol Nurs J; 2000 Dec; 27(6):612-5. PubMed ID: 16649342
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin control, ESA resistance, and regular low-dose IV iron therapy: a review of the evidence.
Singh A
Semin Dial; 2009; 22(1):64-9. PubMed ID: 19175537
[TBL] [Abstract][Full Text] [Related]
6. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
7. Assessing hyporesponse to Epoetin alfa: an algorithm approach: case study of the anemic patient.
Wingard R
Nephrol Nurs J; 2000 Oct; 27(5):517-20. PubMed ID: 16649327
[TBL] [Abstract][Full Text] [Related]
8. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
9. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
10. Infection and inflammation in patients on dialysis: an underlying contributor to anemia and epoetin alfa hyporesponse.
Breiterman-White R
Nephrol Nurs J; 2006; 33(3):319-22; quiz 323-4. PubMed ID: 16859203
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of oral and intravenous iron therapy in haemodialysis patients.
Jenq CC; Tian YC; Wu HH; Hsu PY; Huang JY; Chen YC; Fang JT; Yang CW
Int J Clin Pract; 2008 Mar; 62(3):416-22. PubMed ID: 17511797
[TBL] [Abstract][Full Text] [Related]
12. Route of administration for erythropoiesis-stimulating agents: patient and nursing considerations.
Holloway M
Nephrol Nurs J; 2007; 34(5):527-31. PubMed ID: 18041455
[TBL] [Abstract][Full Text] [Related]
13. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
[TBL] [Abstract][Full Text] [Related]
14. Refining the approach to IV iron use in hemodialysis patients: a post-DRIVE analysis.
Sharma A; Vanderhalt K; Ryan KJ; Sclafani J
Nephrol News Issues; 2010 Apr; 24(4):22-6, 29-35. PubMed ID: 20458992
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
17. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
Singh AK; Hertello P
Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
[TBL] [Abstract][Full Text] [Related]
18. Anemia management protocols: providing consistent hemoglobin outcomes.
Michael M
Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
[TBL] [Abstract][Full Text] [Related]
19. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
20. IV iron therapy and anemia management in patients on hemodialysis: benefits of a revised CQI strategy.
Bowe D
Nephrol Nurs J; 2008; 35(4):371-7, 394; quiz 378-9. PubMed ID: 18782999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
